Pulse Pharma gets DGCI nod for nano-carrier entrapped Vitamin D3 oral dispersion

Pulse Pharma gets DGCI nod for nano-carrier entrapped Vitamin D3 oral dispersion Published – August 20, 2026 09: 41 pm IST – HYDERABAD.

Key points

• Pulse Pharmaceuticals has received approval for its nano-carrier entrapped Vitamin D3 oral dispersion from the Drugs Controller General of India (DCGI).
• The firm stated it holds five patents throughout India, the U.S., Russia, Mexico and Australia.
• It has additionally has filed patents for 4 other proprietary platforms throughout 7 major countries and working on filing 3 more.
• The approval transforms advanced nano pharmaceutical research into a regulated, patient-ready product, the firm stated on Thursday.
• It has developed a number of proprietary platform technologies to effectively deliver medicines.

Meanwhile, the approval transforms advanced nano pharmaceutical research into a regulated, patient-ready product, the firm stated on Thursday.

Founder and Managing Director K. V. Rambabu remarked such an approval is probably first in the world. It is due to pave the way Pulse Pharmaceuticals to take the product to some of the neighbouring South Asian countries besides helping it in seeking regulatory approval in highly regulated markets, including the U.S.

For context, the firm, which he stated has been working in nano pharmaceutical drug delivery since 2010 noted uses nanotechnology to improve how well a drug works, its bioavailability, how easily it is tolerated and the overall patient experience. It has developed a number of proprietary platform technologies to effectively deliver medicines.

Beyond Vitamin D3, Pulse is applying these platforms to other essential nutrients such as Vitamin K2-7, Vitamin B12 and Iron as well as in widely applied medications like Paracetamol, Diclofenac and Ibuprofen, he stated.

Meanwhile, the firm stated it holds five patents throughout India, the U.S., Russia, Mexico and Australia. An EU patent for its Aqueol technology is in the final stages of approval.

It has additionally has filed patents for 4 other proprietary platforms throughout 7 major countries and working on filing 3 more. "Our purpose has always been to identify important unmet needs in drug delivery and develop practical solutions that can make a meaningful difference to patients, " Mr.Rambabu remarked.

In short, pulse Pharma gets DGCI nod for nano-carrier entrapped Vitamin D3 oral dispersion is the central thread here, and readers can expect follow-up reporting as the picture becomes clearer.